Scantox is the leading Nordic preclinical GLP-accredited CRO, focused on pharmacology and regulatory toxicology. We are headquartered in Denmark, in the same location as where the company was originally founded, and in addition Scantox has subsidiaries in Sweden.
Based on decades of experience, we are a trusted partner for product development services within the pharmaceutical, biotech and medical devices industries, and a globally recognized leader for our expertise with Göttingen Minipigs. Our services enable clients to progress their drug or device development based on solid data to the highest technical and scientific standards.
Founded in 1977, Scantox is today owned by Impilo, the leading Nordic healthcare investment company.
Scantox is specialized in preclinical contract research services. Our work enables pharmaceutical and biotechnology companies to progress drug development projects, based on solid high-quality data. Core competencies within the Scantox Group include:
· Explorative and efficacy studies
· General toxicology including Juvenile & EFD
· Local tolerance
· Wound healing
· GLP and GMP compliant
In addition, each of our locations offer a wide range of unique key specialties:
· Infectious disease models (BSL 1-3)
· Stereotactic surgery
· Advanced imaging PET-CT; PET-NMR, MRI
· Oncology, xenograft models
· Metabolic disorders
· Customized animal models incl. orphan diseases
· Juvenile minipig studies incl. feeding studies
· DART in minipigs
· Colony animals
· Safety pharmacology studies
Scantox Services within the Drug Development Process
The drug and device development process timeline can be divided into different lifecycle phases, and it is often a 10+ years process for a new drug to reach the intended market.
Once a lead compound is identified within the drug discovery phase, the preclinical phase of drug development begins with in vivo research to determine the efficacy and safety of the drug. Preclinical trials test the new drug on non-human subjects for efficacy, toxicity, and pharmacokinetic (PK) information.
Scantox’ core business is studies within the Preclinical phase, but we also extend our expertise into in vitro and in vivo studies in early discovery. Scantox is catered towards providing services for both the biopharmaceutical innovative SMEs, as well as the bigger pharma companies on the global arena.
Scantox is your guarantee for solid timelines, on-time and on-budget deliveries, the highest quality scientific data, and a close partnership where you are in contact with a dedicated scientist from start to finish of your study.
GLP Accredited Company
Scantox is your GLP-accredited CRO partner.
The fundamental purpose of the Principles of Good Laboratory Practice (GLP) is to ensure the quality and integrity of test data related to non-clinical studies. The way in which study data is generated, handled, reported, retained and archived has continued to evolve in line with the introduction and ongoing development of supporting technologies. However, the main purpose of the requirements of the Principles of GLP remains the same in having confidence in the quality, the integrity of the data and being able to reconstruct activities performed during the conduct of non-clinical studies.
1977-2005 The beginning
Scantox was originally founded in 1977, in the very same location which is today headquarters for the Scantox Group.
2005-2021 Different ownerships
During the years 2005 to 2021 the company site was under different ownerships, including LAB Research, CitoxLab and most recently Charles River.
2021 Scantox v.2.0
Since January 2021, the company has operated independently under the Scantox name with the Nordic equity fund Impilo as partner. With over 30 years of expertise built around the specialty area of preclinical research, the company is today a highly respected, trusted and valued partner for companies in medical and pharmaceutical industries worldwide. Furthermore, Scantox takes the worldwide lead in research based on the use of Göttingen Minipigs, and the Scantox experts are sought after speakers at conferences all over the world.
2022 An international journey of growth
With the acquisitions of the two Swedish CRO’s Timeline Bioresearch (Lund) and Adlego Biomedical (Solna), Scantox Sweden was added to the Scantox Group, taking the company to the leading position for Scandiavian preclinical CROs. Joining forces with the two highly specialized Swedish market players has added further capabilities to the portfolio of study types offered by Scantox, and marks an important milestone in the company’s journey of growth. Locally in Danmark, Scantox won the prize of Company of the Year 2022 in the Køge region where the Group Headquarters is located.
2023 Great Place To Work® – and the international growth journey continues
In April 2023 Scantox was proudly certified Great Place To Work®. The award is based entirely on what current employees say about their experience of working at Scantox. In August Scantox Sweden was expanded further with the acquisition of Q&Q Labs (Gothenburg), and in November Solural Pharma in Denmark was added to the Group.
From the corporate headquarters in Denmark, Scantox is today serving customers all over the world. And the company is world known for its high quality data, on time deliveries, and high ethical standards.
In 2022 Scantox Sweden was added to the Scantox Group, adding not only new geographical locations, but also an array of complimentary services to the company’s study portfolio.
The Scantox name dates back to 1977. It holds the story of our origination and our original key focus areas of research and expertise – SCANdinavia TOXicology.
HQ Location in Denmark
Headquarters of the Scantox Group is located in Denmark – in Lille Skensved close to Køge, where the company was originally founded back in 1977. The area is within beautiful rural settings and just 30 minutes away from the city center of Copenhagen.